The search for biochemical predictors of the NAT2 phenotype to optimize prophylaxis and pharmacotherapy of hepatic cirrhosis.
Radkevich
L A
LA
Center of Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, Moscow, 119991 Russia.
Korshunov
I B
IB
Pyn'ko
N E
NE
Morozova
N V
NV
Markarova
E V
EV
Nechaev
D S
DS
Piruzyan
L A
LA
D000107:Acetylation; D000328:Adult; D001191:Arylamine N-Acetyltransferase / Q000737:chemistry*; D001663:Bilirubin / Q000737:chemistry / Q000378:metabolism; D002779:Cholestasis / Q000378:metabolism; D005260:Female; D020022:Genetic Predisposition to Disease; D022781:Hepatocytes / Q000378:metabolism; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000473:pathology* / Q000517:prevention & control; D008107:Liver Diseases / Q000175:diagnosis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010641:Phenotype
D001191:Arylamine N-Acetyltransferase; C478900:NAT2 protein, human; D001663:Bilirubin